Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
93.64 USD | -1.38% | -1.49% | -23.33% |
Sales 2023 * | 214 M 227 M | Sales 2024 * | 356 M 377 M | Capitalization | 5 052 M 5 356 M |
---|---|---|---|---|---|
Net income 2023 * | -520 M -551 M | Net income 2024 * | -464 M -492 M | EV / Sales 2023 * | 24,3x |
Net Debt 2023 * | 150 M 159 M | Net Debt 2024 * | 241 M 256 M | EV / Sales 2024 * | 14,9x |
P/E ratio 2023 * | -9,83x | P/E ratio 2024 * | -11,5x | Employees | - |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 10.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +0.42% | ||
1 week | -0.51% | ||
Current month | -3.13% | ||
1 month | -3.57% | ||
3 months | +9.16% | ||
6 months | -13.46% | ||
Current year | -22.25% |
1 week
91.59
96.68

1 month
91.59
106.45

Current year
64.33
127.77

1 year
64.33
134.53

3 years
61.58
183.98

5 years
53.21
183.98

10 years
11.92
183.98

Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 93.64 | -1.38% | 235 983 |
23-09-28 | 94.95 | +0.94% | 205,004 |
23-09-27 | 94.07 | -0.15% | 197,508 |
23-09-26 | 94.21 | -1.35% | 331,333 |
23-09-25 | 95.50 | +0.46% | 180,510 |
Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT
More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Calendar
2023-11-28
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
BUY
Number of Analysts
12
Last Close Price
89.86EUR
Average target price
132.91EUR
Spread / Average Target
+47.91%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-22.25% | 5 338 M $ | |
+4.17% | 3 105 M $ | |
+1293.43% | 358 M $ | |
+16.84% | 71 M $ | |
-47.70% | 74 M $ | |
0.00% | 1 218 M $ | |
-4.84% | 174 M $ | |
+52.24% | 89 M $ | |
0.00% | 1 335 M $ | |
+57.22% | 67 M $ |